Search Result

Results for "

MOLM-13

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (15) Autophagy (1) Bcl-2 Family (1) Caspase (1) CDK (5) Dihydroorotate Dehydrogenase (1) E3 Ligase Ligand-Linker Conjugates (4) Epigenetic Reader Domain (9) Eukaryotic Initiation Factor (eIF) (1) FLT3 (12) Histone Acetyltransferase (1) Histone Demethylase (1) Histone Methyltransferase (5) Ligands for Target Protein for PROTAC (1) MAP4K (1) MDM-2/p53 (2) METTL3 (2) Microtubule/Tubulin (1) MNK (1) PI3K (1) Pim (1) PROTAC Linkers (2) PROTACs (6) RET (1) ROS Kinase (1) STAT (1) Trk Receptor (1)
By Research Areas:	Cancer (54) Cardiovascular Disease (1) Endocrinology (1) Infection (1)

By Targets:

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (15)

Autophagy (1)

Bcl-2 Family (1)

Caspase (1)

CDK (5)

Dihydroorotate Dehydrogenase (1)

E3 Ligase Ligand-Linker Conjugates (4)

Epigenetic Reader Domain (9)

Eukaryotic Initiation Factor (eIF) (1)

FLT3 (12)

Histone Acetyltransferase (1)

Histone Demethylase (1)

Histone Methyltransferase (5)

Ligands for Target Protein for PROTAC (1)

MAP4K (1)

MDM-2/p53 (2)

METTL3 (2)

Microtubule/Tubulin (1)

MNK (1)

PI3K (1)

Pim (1)

PROTAC Linkers (2)

PROTACs (6)

RET (1)

ROS Kinase (1)

STAT (1)

Trk Receptor (1)

By Research Areas:

Cancer (54)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (1)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: CX3CR1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-115881

SR-1114	PROTACs	Cancer
SR-1114 is a first-in-class PROTAC ENL degrader. SR-1114 elicits rapid, CRBN-dependent degradation of ENL with DC₅₀s of 150 nM, 311 nM, and 1.65 μM in MV4;11 , MOLM-13, and OCI/AML-2 cells, respectively .

HY-101520A

Dot1L-IN-1 TFA	Histone Methyltransferase	Cancer
Dot1L-IN-1 TFA is a highly potent and selective Dot1L inhibitor with a K_i of 2 pM and an IC₅₀ of <0.1 nM. Dot1L-IN-1 TFA potently suppresses H3K79 dimethylation (IC₅₀=3 nM), as well as the activity of the HoxA9 promoter (IC₅₀=17 nM) in HeLa and Molm-13 cells, respectively .

HY-156641

Sontigidomide

Others Cancer

Sontigidomide (Compound 5) is an antineoplastic compound. Sontigidomide inhibits MOLM-13 cell proliferation more than 80% at 1 μM (3 days) .

Sontigidomide	Others	Cancer
Sontigidomide (Compound 5) is an antineoplastic compound. Sontigidomide inhibits MOLM-13 cell proliferation more than 80% at 1 μM (3 days) .

HY-162230

PRMT5-IN-33	Apoptosis Histone Methyltransferase	Cancer
PRMT5-IN-33 (compound A8) is a selective, SAM-competitve PRMT5 inhibitors with IC₅₀ of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity .

HY-101520

Dot1L-IN-1	Histone Methyltransferase	Cancer
Dot1L-IN-1 is a highly potent and selective Dot1L inhibitor with a K_i of 2 pM and an IC₅₀ of <0.1 nM. Dot1L-IN-1 potently suppresses H3K79 dimethylation (IC₅₀=3 nM), as well as the activity of the HoxA9 promoter (IC₅₀=17 nM) in HeLa and Molm-13 cells, respectively .

HY-161324

Tubulin degrader 1	Microtubule/Tubulin	Cancer
Tubulin degrader 1 (Compound 5i) is a BML284 (HY-19987) derivative that is an orally active colchicine-site noncovalent tubulin degradation agent with IC₅₀ values ranging from 0.02 to 0.05 μM against the five tumor cell lines (Hela, HCT116, MCF-7, K562 and Molm-13). Tubulin degrader 1 has antiproliferative activity that effectively suppressed tumor growth .

HY-155770

FLT3-IN-20	FLT3	Cancer
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC₅₀ values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer .

HY-115906

K783-0308	FLT3 MNK Apoptosis	Cancer
K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC₅₀ values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC₅₀=10.5 µM) and MV-4-11 (IC₅₀=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase .

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective LSD1/KDM1A inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research .

HY-162293

CDK8-IN-14	CDK	Cancer
CDK8-IN-14 (compound 12) inhibits CDK8 with an IC₅₀ value of 39.2 nM and has anti-AML cell proliferation activity (molm-13 GC50 = 0.02±0.01μM, MV4-11 GC50 = 0.03±0.01μM) .

HY-156759

METTL3-IN-5	METTL3	Cancer
METTL3-IN-5 (Compound 13) is a METTL3 inhibitor. METTL3-IN-5 inhibits MOLM-13 growth with an IC₅₀ less than 2 μM. METTL3-IN-5 has weak hERG inhibitory activity (IC₅₀ >30 μM). METTL3-IN-5 can be used for AML research .

HY-115446A

Lenalidomide-C4-NH2 hydrochloride Cereblon ligand 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 32 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-C4-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C4-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC (Compound 24), which has IC₅₀s of 0.98 nM and 13.7 nM in inhibition of RS4;11 and MOLM-13 acute leukemia cell lines growth, respectively .

HY-147716

CDK8-IN-6	CDK	Cancer
CDK8-IN-6 (compound 9) is a potent cyclin-dependent kinase 8 (CDK8) inhibitor with an K_d of 13 nM. CDK8-IN-6 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC₅₀s of 11.2, 7.5, 8.6, 20.5, 12.5-25 µM, respectively. CDK8-IN-6 has the potential for the research of AML-cancer .

HY-147717

CDK8-IN-7	CDK	Cancer
CDK8-IN-7 (compound 12) is a potent and selective cyclin-dependent kinase 8 (CDK8) inhibitor with an K_d of 3.5 nM. CDK8-IN-7 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC₅₀s of 5.9, 4.8, 5.4, 16.2, 12.5-25 µM, respectively. CDK8-IN-7 has the potential for the research of AML-cancer .

HY-149522

WK499	Bcl-2 Family Apoptosis	Cancer
BCL6-IN-10 (Compound WK499) is a BCL6 inhibitor. BCL6-IN-10 interrupts the binding of BCL6 to SMRT protein. BCL6-IN-10 induces cell apoptosis, cell cycle arrest and DNA damage. BCL6-IN-10 inhibits AML cell proliferation (IC₅₀s: 0.91, 1.63, 1.026, 7.42, 0.87, 0.85μM for OCl-AML3, THP1, MOLM13, HL60, KG1, NB4 cell respectively) .

HY-152470

Eleven-Nineteen-Leukemia Protein IN-2	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-2 (compound 23) is an Eleven-Nineteen-Leukemia Protein (ENL) inhibitor with an IC₅₀ value of 10.7 nM. Eleven-Nineteen-Leukemia Protein IN-2 can be used for the research of leukemia .

HY-154997

7OQL

METTL3 Cancer

7OQL (compound 54) is a selective METTL3 inhibitor (IC₅₀=0.054 µM). 7OQL has the potential to be used in the study of cancer .

7OQL	METTL3	Cancer
7OQL (compound 54) is a selective METTL3 inhibitor (IC₅₀=0.054 µM). 7OQL has the potential to be used in the study of cancer .

HY-W650842

Boc-Asp(OBzl)-CMK	Caspase	Cancer
Boc-Asp(OBzl)-CMK is an inhibitor for IL-1 converting enzyme (ICE, caspase1). Boc-Asp(OBzl)-CMK prevents death of CHP100 neuroblastoma cell, and IL-1β release elicited by the viral coat protein .

HY-P10238

MYBMIM

Apoptosis Cancer

MYBMIM is an inhibitor for assembly of the molecular MYB:CBP/P300 complex. MYBMIM inhibits growth of leukemia cells .

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular MYB:CBP/P300 complex. MYBMIM inhibits growth of leukemia cells .

HY-148422

Rohinitib	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-152471

Eleven-Nineteen-Leukemia Protein IN-3	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-3 is an orally active inhibitor of ENL YEATS domain with an IC₅₀ value of 15.4 nM. Eleven-Nineteen-Leukemia Protein IN-3 down-regulates MYC expression through ENL in cells and can enhances the thermal stability of ENL protein in vitro .

HY-144709

FLT3/ITD-IN-1	FLT3	Cancer
FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 38.2 nM and 144.1 nM against FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144710

FLT3/ITD-IN-2	FLT3	Cancer
FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 1.0 nM against FLT3 ^D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144711

FLT3/ITD-IN-3	FLT3	Cancer
FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 0.9 nM against FLT3 ^D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-152469

Eleven-Nineteen-Leukemia Protein IN-1	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-1 is an inhibitor of ENL YEATS domain with an IC₅₀ value of 14.5 nM. Eleven-Nineteen-Leukemia Protein IN-1 interacts with ENL protein and enhances the thermal stability of ENL protein in vitro .

HY-148333

MS177	PROTACs Histone Methyltransferase Apoptosis	Cancer
MS177 is an effective and fast-acting EZH2 degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC₅₀): 12 nM). MS177 effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest .

HY-163442A

PIM3-IN-1 hydrochloride	Pim	Cancer
PIM3-IN-1 hydrochloride (Compound 19a) is an inhibitor of (PIM2/3), with the highest inhibition level being against PIM3, having an IC₅₀ value in the nanomolar range. PIM3-IN-1 hydrochloride can be used in cancer research .

HY-158147

PI3Kδ-IN-20	PI3K	Cancer
PI3Kδ-IN-20 (compound ( S )-36) is a potent inhibitor of PI3Kδ, with the IC₅₀ of 6.4 nM. PI3Kδ-IN-20 has oral bioactivity. PI3Kδ-IN-20 shows significant suppression of cell proliferation and remarkable induction of apoptosis both in vitro and in vivo .

HY-161494

XYD190	PROTACs Epigenetic Reader Domain	Cancer
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC₅₀ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .

HY-161498

XYD198	PROTACs Epigenetic Reader Domain	Cancer
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC₅₀ of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))

HY-154984

JET-209	Histone Acetyltransferase PROTACs	Cancer
JET-209 is a potent PROTAC CBP/p300 degrader, with DC₅₀ values of 0.05 nM and 0.2 nM for CBP and p300. JET-209 contains Lenalidomide (HY-A0003) (the cereblon ligand), a linker and GNE-207 (HY-120028) (bromodomain Inhibitor). JET-209 is used for cancer research .

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-161496

Boc-NHCH2-Ph-Py-NH2

PROTAC Linkers Cancer

Boc-NHCH2-Ph-Py-NH2 is the linker for PROTAC molecule XYD190 (HY-161494) .

Boc-NHCH2-Ph-Py-NH2	PROTAC Linkers	Cancer
Boc-NHCH2-Ph-Py-NH2 is the linker for PROTAC molecule XYD190 (HY-161494) .

HY-161497

Thalidomide-benzylamine-Py-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-benzylamine-Py-NH2 is a conjugate of E3 ligase and linker, which is consisted of a Thalidomide (HY-14658) and the Linker Boc-NHCH2-Ph-Py-NH2 (HY-161496). Thalidomide-benzylamine-Py-NH2 is utilized for synthesis of PROTAC molecule XYD190 (HY-161494) .

HY-161499

Boc-NHCH2-Ph-pyrimidine-NH2

PROTAC Linkers Cancer

Boc-NHCH2-Ph-pyrimidine-NH2 is the linker for PROTAC molecule XYD198 (HY-161498) .

Boc-NHCH2-Ph-pyrimidine-NH2	PROTAC Linkers	Cancer
Boc-NHCH2-Ph-pyrimidine-NH2 is the linker for PROTAC molecule XYD198 (HY-161498) .

HY-161500

Thalidomide-NHCH2-Ph-pyrimidine-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NHCH2-Ph-pyrimidine-NH2 is a conjugate of E3 ligase ligand and linker, which is consisted of a Thalidomide (HY-14658) and a Linker Boc-NHCH2-Ph-pyrimidine-NH2 (HY-161499). Thalidomide-NHCH2-Ph-pyrimidine-NH2 is utilized for synthesis of PROTAC molecule XYD198 (HY-161498) .

HY-N2037A

Higenamine hydrochloride 1 Publications Verification Norcoclaurine hydrochloride	MDM-2/p53 ROS Kinase Apoptosis	Infection Cardiovascular Disease Endocrinology Cancer
Higenamine hydrochloride is a selective LSD1 inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-143286

PF15	PROTACs FLT3	Cancer
PF15 is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 is a high selective FLT3-ITD degrader, with a DC₅₀ of 76.7 nM. PF15 significantly inhibits the proliferation of FLT3-ITD-positive cells, can down-regulate the phosphorylation of FLT3 and STAT5. PF15 also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-162037

CDDD11-8	CDK FLT3	Cancer
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with K_i values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation .

HY-145409

SR-0813	Epigenetic Reader Domain	Cancer
SR-0813 is a potent and selective ENL/AF9 YEATS domain inhibitor. SR-0813 has IC₅₀ and EC₅₀ values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC₅₀ and EC₅₀ values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively. SR-0813 binds MAP3K19 with over 100-fold lower affinity (K_d=3.5 μM) than ENL YEATS (K_d=30 nM). SR-0813 can be used for the research of acute leukemia .

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .

HY-143317

XY153	Epigenetic Reader Domain	Cancer
XY153 (compound 8l) is a BD2-selective BET inhibitor and selectively binds to BRD4 BD2. XY153 binds to BRD4 BD2, BRD3 BD2 and BRD2 BD2 with IC₅₀s of 0.79, 5.31 and 5.09 nM, respectively. XY153 shows potent antiproliferative activity against multiple tumor cell lines. XY153 can be used for the research of acute myeloid leukemia (AML) and cancer .

HY-130853

Thalidomide-NH-PEG2-C2-NH-Boc	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis. dBRD9 is a selective BRD9 probe PROTAC degrader for the study of BAF complex biology .

HY-144777

FLT3-IN-14	FLT3 Apoptosis	Cancer
FLT3-IN-14 is a potent FLT3 inhibitor with IC₅₀s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model .

HY-146680

FLT3/ITD-IN-4	FLT3 RET CDK MAP4K	Cancer
FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC₅₀ of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research .

HY-160018

BAY-155	Epigenetic Reader Domain	Cancer
BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC₅₀ of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models .

HY-146749

FLT3/TrKA-IN-1	FLT3 Trk Receptor Apoptosis	Cancer
FLT3/TrKA-IN-1 is a potent FLT3/TrKA dual kinase inhibitor with the IC₅₀s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML) .

HY-151425

TDO-IN-1	Others	Cancer
TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC₅₀ value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks